New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
09:22 EDTSTJSt. Jude Medical warning letter not clearing event, says Citigroup
Citigroup believes the next FDA action regarding St. Jude Medical's Sylmar is likely to be a threat of injunction that normally leads to a consent decree. Further, Citi believes the FDA will ultimately have to make a determination on the safety of Durata, with the firm still believing a recall is likely. Citi says the FDA's Sylmar Warning Letter is not a clearing event, but the next step in a process that looks ominous for St. Jude. The firm keeps a Sell rating on the stock with a $32 price target.
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:02 EDTSTJOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:57 EDTSTJSt. Jude Medical initiated with a Strong Buy at Needham
Subscribe for More Information
September 23, 2014
09:45 EDTSTJLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy discusses the ultimate market opportunity for leadless pacers and compares Medtronic vs St. Jude Medical on an Analyst/Industry conference call to be held on September 24 at 2 pm.
September 22, 2014
08:32 EDTSTJSt. Jude receives CE Mark approval of Tendril STS, IsoFlex Optim labeling
Subscribe for More Information
06:51 EDTSTJSt. Jude Medical recent weakness a buying opportunity, says Barclays
Barclays said St. Jude Medical weakness is a buying opportunity. The analyst said CardioMEMS is underappreciated by the Street and valuation compelling given sequential revenue growth. Shares are Overweight rated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use